Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro
- PMID: 10862016
- DOI: 10.1002/1097-0347(200007)22:4<341::aid-hed5>3.0.co;2-3
Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro
Abstract
Background: Human squamous cell carcinomas of the head and neck (SCCHN) overexpress the protein kinase CK2, and elevated CK2 activity correlates with aggressive tumor behavior and poor clinical outcome. We therefore investigated whether interference with CK2 expression would inhibit SCCHN cell growth in vitro.
Methods: We targeted the catalytic (alpha) subunit of CK2 using an antisense oligodeoxynucleotide (ODN) strategy. Human Ca9-22 cells derived from SCCHN were transfected with CK2-alpha sense, nonsense, or antisense ODN; CK2 activity was measured; and the effect on CK2 activity and on cell growth was determined.
Results: Transfection of Ca9-22 cells with antisense CK2-alpha ODN resulted in significantly decreased CK2 kinase activity associated with nuclear chromatin and in dose-dependent growth inhibition of Ca9-22 cells in vitro.
Conclusions: Interference with the protein kinase CK2 signal in SCCHN cells may offer a novel anticancer strategy for this malignancy.
Copyright 2000 John Wiley & Sons, Inc.
Similar articles
-
Response of cancer cells to molecular interruption of the CK2 signal.Mol Cell Biochem. 2001 Nov;227(1-2):167-74. Mol Cell Biochem. 2001. PMID: 11827168
-
Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck.Mol Med. 1995 Sep;1(6):659-66. Mol Med. 1995. PMID: 8529132 Free PMC article.
-
Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells.Int J Biochem Cell Biol. 1999 Sep;31(9):941-9. doi: 10.1016/s1357-2725(99)00050-3. Int J Biochem Cell Biol. 1999. PMID: 10533285
-
Targeting CK2 for cancer therapy.Anticancer Drugs. 2005 Nov;16(10):1037-43. doi: 10.1097/00001813-200511000-00001. Anticancer Drugs. 2005. PMID: 16222144 Review.
-
Protein kinase CK2 signal in neoplasia.Histol Histopathol. 2001 Apr;16(2):573-82. doi: 10.14670/HH-16.573. Histol Histopathol. 2001. PMID: 11332713 Review.
Cited by
-
The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015. Front Pharmacol. 2015. PMID: 25873900 Free PMC article.
-
Protein kinase CK2--a key suppressor of apoptosis.Adv Enzyme Regul. 2008;48:179-87. doi: 10.1016/j.advenzreg.2008.04.002. Epub 2008 Apr 30. Adv Enzyme Regul. 2008. PMID: 18492491 Free PMC article. Review. No abstract available.
-
CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.Pharmaceuticals (Basel). 2017 Jan 28;10(1):18. doi: 10.3390/ph10010018. Pharmaceuticals (Basel). 2017. PMID: 28134850 Free PMC article. Review.
-
Protein kinase CK2, an important regulator of the inflammatory response?J Mol Med (Berl). 2008 Aug;86(8):887-97. doi: 10.1007/s00109-008-0352-0. Epub 2008 Apr 25. J Mol Med (Berl). 2008. PMID: 18437331 Review.
-
Structural and functional insights into the regulation mechanism of CK2 by IP6 and the intrinsically disordered protein Nopp140.Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19360-5. doi: 10.1073/pnas.1304670110. Epub 2013 Nov 11. Proc Natl Acad Sci U S A. 2013. PMID: 24218616 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical